The following assessments were made in the final part of the study: (a) whether the development of tumor-specific immune response elicited by in situ vaccination targeting Ehrlich carcinoma can affect the genetically distinct A20 B cell lymphoma and (b) the efficacy of OX40 and PD1 aptamers for the proposed regimen of in situ vaccination. The gene discussed is TNFRSF4; the disease is B-cell non-Hodgkin lymphoma.